Nuvation Bio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Nuvation Bio sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Nuvation Bio: 7 sponsored US clinical trials, 2 recruiting.
Nuvation Bio sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Platinum-resistant Ovarian Cancer (PROC), with 1 trials.
Upper-quartile sponsor footprint
Nuvation Bio sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05252390
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
NCT04541225
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
NCT02279433
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Nuvation Bio pipeline
2 recruiting of 7 indexed (29% open); 1 completed (14%).
Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Platinum-resistant Ovarian Cancer (PROC) (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nuvation Bio: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Nuvation Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Nuvation Bio page
7 registered trials is a research-attention snapshot, not an endorsement of Nuvation Bio or any single study.
- 2 of Nuvation Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Platinum-resistant Ovarian Cancer (PROC) is the condition Nuvation Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Platinum-resistant Ovarian Cancer (PROC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Nuvation Bio pipeline card: 7 registered trials from official public datasets.Report a data error.